Fundz

Who to call at Valion Bio, Inc., and when

Fundz watches for the moments Valion Bio, Inc. starts buying, and tells you who to reach.

  • An alert the day Valion Bio, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Valion Bio, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Valion Bio, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNegative

Valion Bio, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

tivichealth.com
Filed: Nov 2, 2026San Antonio, TexasCIK: 0001787740Biotechnology
Full company profileView on SEC.gov

Leadership shakeup: 4 executive changes at Tivic in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.

The seat is still open. No replacement has been named 20 days after this filing.

See every company with multiple executive changes →

Executive Summary

Analysis of 8-K filing content

Valion Bio terminated General Counsel and Senior Vice President Melinda Lackey on October 30, 2026, and executed a separation agreement providing $26,750 in severance and COBRA coverage through November 30, 2026. This executive departure reflects the company's strategic restructuring.

Quick answer

Valion Bio, Inc. filed a Form 8-K with the SEC on November 2, 2026 under Item 5.02 (Executive Change). Valion Bio terminated General Counsel and Senior Vice President Melinda Lackey on October 30, 2026, and executed a separation agreement providing $26,750 in severance and COBRA coverage through November 30, 2026.

What did Valion Bio, Inc. disclose in its 8-K filed November 2, 2026?
Valion Bio terminated General Counsel and Senior Vice President Melinda Lackey on October 30, 2026, and executed a separation agreement providing $26,750 in severance and COBRA coverage through November 30, 2026. This executive departure reflects the company's strategic restructuring.
What does 8-K Item 5.02 (Executive Change) mean?
A senior executive or director joined, left, or changed roles. Companies generally must file it within four business days of the event.
Which other companies filed an 8-K Item 5.02 around the same time?
Commercial Vehicle Group, Inc. (November 2, 2026), Chord Energy Corporation (November 2, 2026), Elme Communities (November 2, 2026) and UPWORK, INC (November 2, 2026) also filed an Item 5.02 8-K within a week of Valion Bio, Inc.
Where can I read the original Valion Bio, Inc. filing?
The original filing is on SEC EDGAR (CIK 0001787740), accession number 0001683168-26-008221.

Source: Fundz verified event record.

Other companies that filed an 8-K Item 5.02 (Executive Change) the same week

Analyzed filings with the same item number within 7 days, from SEC EDGAR via Fundz.

  • Commercial Vehicle Group, Inc. (November 2, 2026): Commercial Vehicle Group appointed David Ruppel as President and CEO effective November 9, 2026, succeeding James R. Ray, Jr., who will transition to Senior Advisor through...
  • Chord Energy Corporation (November 2, 2026): Chord Energy's Board approved significant compensation increases for newly appointed President & CEO Mr. Lou, including a $950,000 annual base salary, 125% performance-based cash...
  • Elme Communities (November 2, 2026): Elme Communities terminated retention agreements with three key officers (Paul McDermott, Tiffany Butcher, and W. Drew Hammond) effective November 6, 2026, in connection with the...
  • UPWORK, INC (November 2, 2026): Upwork announced the appointment of Peter Sanborn as Chief Financial Officer effective January 1, 2027, following the resignation of Erica Gessert.
  • Lindsay Corporation (November 2, 2026): Lindsay Corporation appointed Michael Koch as Senior Vice President and Chief Financial Officer, effective November 9, 2026, replacing interim co-CFOs Brett Coburn and Alicia...
  • Frontier Group Holdings, Inc. (November 2, 2026): Frontier Group Holdings appointed Michael Delehant as Executive Vice President and Chief Operating Officer, effective November 30, 2026.

Key Takeaways

General Counsel Melinda Lackey's employment was terminated effective October 30, 2026, following notification on October 27, 2026

Separation agreement includes $26,750 gross severance payment, COBRA premium coverage until November 30, 2026, and general release of claims

3 more takeaways

Related Filings (6)

6 more filings from Valion Bio, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateNov 2, 2026
Item5.02
CategoryExecutive Change
CIK0001787740
Accession #0001683168-26-008221
Risk LevelMEDIUM
SentimentNegative
Signalrisk
Topics
executive departureleadership transitionrestructuring

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

Valion Bio, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.